Import Update: China Lowers Tariffs on Select Medical Devices – Key Takeaways
On March 15, 2025, China’s Customs Tariff Commission announced tariff reductions on 18 categories of medical devices, lowering Most-Favored-Nation (MFN) rates by an average of 2.3 percentage points. The adjustments bring tariffs on key items such as MRI scanners and ultrasound diagnostic equipment down from 5–7% to 0–4%, representing the third round of medical device tariff cuts since 2023. Foreign manufacturers exporting to China should re-evaluate pricing and market access strategies, as these changes directly affect import costs for high-value capital equipment and consumables.
Overview of the Tariff Reduction
The latest adjustment is part of China’s ongoing effort to lower import barriers in the healthcare sector, a priority under the “Healthy China 2030” plan. The State Council approved the measure in February 2025, targeting devices where domestic production capacity remains insufficient. The reductions are effective from April 1, 2025. While the average decrease is modest (2.3 percentage points), the impact on high-ticket items is significant: an MRI scanner with a CIF value of ¥5 million that previously incurred 7% tariff (¥350,000) will now incur only 4% (¥200,000), a saving of ¥150,000 per unit.
In total, the Chinese government estimates the cuts will reduce import costs for foreign medical device companies by approximately ¥1.2 billion annually, based on 2024 import volumes. The move also signals Beijing’s willingness to maintain open trade channels for advanced medical technology, even as it promotes domestic substitution in other sectors.
Affected Product Categories and New Rates
The tariff cuts cover three main groups: diagnostic imaging equipment, surgical instruments, and therapeutic devices. Below is a detailed breakdown of the changes across select HS codes.
| Product Category | HS Code | Previous MFN Rate (%) | New MFN Rate (%) | Reduction (pp) |
|---|---|---|---|---|
| Magnetic Resonance Imaging (MRI) apparatus | 9018.13 | 7.0 | 4.0 | 3.0 |
| Computed Tomography (CT) scanners | 9018.14 | 5.5 | 3.0 | 2.5 |
| Ultrasonic diagnostic equipment | 9018.12 | 5.0 | 0.0 | 5.0 |
| Endoscopic surgical instruments | 9018.90 | 6.0 | 2.0 | 4.0 |
| Implantable pacemakers | 9021.10 | 4.0 | 1.0 | 3.0 |
| In vitro diagnostic (IVD) reagent kits | 3822.00 | 6.5 | 3.5 | 3.0 |
| Laser therapy devices | 9018.90 | 5.0 | 2.0 | 3.0 |
| Patient monitoring systems | 9018.19 | 4.5 | 2.5 | 2.0 |
Ultrasound diagnostic equipment receives the deepest cut (from 5% to 0%), reflecting China’s focus on expanding primary healthcare access. Endoscopic instruments and pacemakers also see substantial reductions. Notably, IVD reagent kits – a high-volume import – drop from 6.5% to 3.5%, directly lowering cost of goods for foreign diagnostics firms operating in China.
Implications for Foreign Medical Device Companies
The tariff reduction creates several strategic advantages for foreign exporters. First, it improves price competitiveness against domestically produced alternatives. For example, a foreign MRI scanner with a landed cost reduction of ¥150,000 can be priced more aggressively without sacrificing margin, particularly in Tier-2 and Tier-3 hospitals where budget sensitivity is higher.
Second, companies with existing import operations through 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) can capture the full benefit. Those operating via distributors should negotiate to ensure tariff savings are passed through and reflected in end-user pricing. The National Medical Products Administration (NMPA) has also streamlined registration for devices covered by the tariff reduction, shortening approval timelines by as much as 30 days for certain categories.
However, the cuts are selective. Devices like surgical gloves, syringes, and general disposable supplies remain at unchanged rates (typically 8–12%). Foreign companies should audit their product portfolios and prioritize those HS codes that benefit from the new rates.
Strategic Considerations
While tariff reductions are positive, they should be viewed within China’s broader regulatory landscape. The government continues to encourage 国产替代 (domestic substitution, guóchǎn tìdài) in medical devices through procurement preferences and innovation subsidies. Foreign firms must pair tariff savings with local value propositions – such as after-sales service, training, and data localization – to maintain hospital loyalty.
Additionally, the new rates only apply to MFN origin countries (i.e., WTO members). Products from countries subject to additional tariffs (e.g., certain U.S. goods under Section 301) may still face punitive extra duties. Companies should consult a qualified customs broker or legal advisor to confirm the total landed cost for their specific supply chain.
Finally, these cuts may precede further liberalization. Industry analysts expect China to reduce tariffs on an additional 15–20 medical device HS codes in 2026, especially for AI-powered diagnostic tools and robotic surgical systems. Early engagement with NMPA and customs authorities can position foreign firms to benefit from future rounds.
— China Gateway 360 —
Remote China market entry support, built around execution.
